A drug used to treat angina may lengthen lifespan: Ranolazine-based therapy for life-span extension: Ranolazine (trade name: Ranexa) may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 17/August/2018, 11.36 pm

Relax(in) your way to keep the cardiac diseases at bay: Relaxin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  Relaxin, a reproductive hormone,  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down-regulation of its target gene, 17/August/2018, 11.19 pm
August 17, 2018
Unknown function of the known reproductive hormone Progesterone (P4) in Anti-metastasis therapy: Progesterone (P4), an endogenous steroid hormone, inhibits the expression of a number of enzymes in the glycolytic cycle and suppresses proliferation, migration, invasion, tumorigenesis, and metastasis, via upregulation of its target gene, 17/August/2018, 11.45 am
August 17, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: A drug used to treat angina may lengthen lifespan: Ranolazine-based therapy for life-span extension: Ranolazine (trade name: Ranexa) may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes


From research findings to Therapeutic Opportunity: 

This study suggests, for the first time, that Ranolazineby increasing the expression of their target gene, they may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (fig. 1).

Figure 1. Ranolazine may extend  mammalian lifespan via up-regulation of BuBR1 and down-regulation of p70 S6 Kinase

Figure 2. Ranolazine functions as a longevity-promoting agent  (fig 1).

 

 

 

 

 

 

 

 

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median lifespan. Thus, Ranolazine or its analogs, either alone or in combination with other drugs, may be used to extend the lifespan of an individual (fig.2).

[easy_payment currency=”USD”]


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $750#

Undisclosed mechanistic information: How Ranolazine increase the expression of BubR1 and extend mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., A drug used to treat angina may lengthen lifespan: Ranolazine-based therapy for life-span extension: Ranolazine (trade name: Ranexa) may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 17/August/2018, 11.36 pm,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.